Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer .Poly(ADP)-ribose polymerase inhibition:frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval .Oral poly(ADP-ribo ......